Options to purchase securities

GLAND PHARMA LIMITED GLAND September 13, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor 25th floor, Dalal Street Plot no. C-1, Block G, Bandra Kurla Complex Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 543245 Symbol: GLAND (ISIN: INE068V01023) Dear Sir/Madam, Sub: Grant of Stock Options under Gland Pharma Employee Stock Option Scheme 2025 (“ESOP 2025” or “Scheme”) In continuation to our intimation dated May 15, 2026 and July 30, 2026, we would like to inform you that the ESOP Compensation Committee of the Board of Directors of the Company in its Meeting held on September 13, 2026, has approved the grant of 5,90,249 (Five Hundred Ninety Thousand Two Hundred Forty Nine only) Employee Stock Options to 124 (One Hundred and Twenty-Four only) employees of the Company, under the Gland Pharma Employee Stock Options Scheme, 2025. The grant of the above stock options is in line with the provisions of the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021 as amended from time to time. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure A. This is for your information and records. Yours truly, For Gland Pharma Limited Sampath Kumar Pallerlamudi Company Secretary & Compliance Officer Encl: As above Regd. Office: Corporate Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads Plot No. 11 & 84, TSIIC Phase: IV D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Pashamylaram (V), Patancheru (M), Sangareddy District Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Hyderabad 502307, Telangana, India Tel: +91-40-30510999 Fax: +91 0-30510800 Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLAND Continuation Sheet Annexure A S. Particulars Details 1 Brief details of options granted Grant of 5,90,249 (Five Hundred Ninety Thousand Two Hundred Forty-Nine only) options under ESOP 2025 to 124 (One Hundred and Twenty-Four only) employees of the Company 2 Whether the scheme is in terms of the SEBI Yes (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (if applicable) 3 Total number of shares covered by these 5,90,249 (Five Hundred Ninety Thousand options Two Hundred Forty-Nine only) 4 Pricing formula/ Exercise Price / Grant Price 3,89,564 (Three Hundred Eighty Nine Thousand Five Hundred Sixty Four only) options at INR 1,461.15 (Rupees Fourteen Hundred and Sixty-One and Fifteen paise only) (50% of the closing price of the Equity share on NSE on the date of Grant i.e., September 13, 2026; since the grant date is falling on a trading holiday the closing price of the latest preceding trading day i.e. September 11, 2026 is considered) 2,00,685 (Two Hundred Thousand Six Hundred and Eighty-Five only only) options at INR 1/- (Rupee One only) i.e., the face value of the Equity share 5 Options vested / vesting schedule (i) 34% of the total Granted options will vest on completion of first year from the date of vesting i.e., September 13, 2027 (ii) 33% of the total Granted options will vest on completion of second year from the date of vesting i.e., September 13, 2028 (iii) 33% of the total Granted options will vest on completion of third year from the date of vesting i.e., September 13, 2029 6 Time within which option may be exercised Within a maximum period of two years from the date of vesting GLAND Continuation Sheet 7 Brief details of significant terms Stock options granted under ESOP 2025 will be administered by the ESOP Compensation Committee of the Board of Directors of the Company. 8 Options exercised Not Applicable 9 Money realized by exercise of options Not Applicable 10 The total number of shares arising as a result Not Applicable of exercise of option 11 Options lapsed Not Applicable 12 Variation of terms of options Not Applicable 13 Subsequent changes or cancellation or Not Applicable exercise of such options 14 Diluted earnings per share pursuant to issue Not Applicable of equity shares on exercise of options